{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    13,
    14,
    15,
    16,
    19,
    20,
    21,
    22,
    23
  ],
  "modelUsed": "claude-opus-4-5",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Ontamalimab 75 mg",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Participants receive ontamalimab 75 mg administered subcutaneously every 4 weeks (Q4W) starting on Day 1, with the last dose administered at Week 20 (total treatment period is 24 weeks)"
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Noncirrhotic (F1-F3)",
        "instanceType": "StudyCohort",
        "characteristic": "Participants with NASH and liver fibrosis stage F1, F2, or F3 (noncirrhotic)"
      },
      {
        "id": "cohort_2",
        "name": "Compensated Cirrhotic (F4cc)",
        "instanceType": "StudyCohort",
        "characteristic": "Participants with NASH and liver fibrosis stage F4 compensated cirrhotic"
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 3,
      "cohortCount": 2
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "armIds": [
        "arm_1"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Hepatology",
        "Gastroenterology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": null,
      "therapeuticAreas": [
        "Hepatology",
        "Gastroenterology"
      ]
    },
    "arms": [
      {
        "name": "Ontamalimab 75 mg",
        "type": "Experimental Arm",
        "description": "Participants receive ontamalimab 75 mg administered subcutaneously every 4 weeks (Q4W) starting on Day 1, with the last dose administered at Week 20 (total treatment period is 24 weeks)"
      }
    ],
    "cohorts": [
      {
        "name": "Noncirrhotic (F1-F3)",
        "characteristic": "Participants with NASH and liver fibrosis stage F1, F2, or F3 (noncirrhotic)"
      },
      {
        "name": "Compensated Cirrhotic (F4cc)",
        "characteristic": "Participants with NASH and liver fibrosis stage F4 compensated cirrhotic"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 10 weeks (may be extended up to 12 weeks for SARS-CoV-2 positive participants, or up to 24 weeks for F4cc participants pending safety data)"
      },
      {
        "name": "Treatment",
        "description": "24 weeks (ontamalimab administered Q4W from Day 1 through Week 20)"
      },
      {
        "name": "Follow-up",
        "description": "12 weeks after last dose of study drug"
      }
    ]
  }
}